Literature DB >> 33572615

Antiproliferative Activity and Potential Mechanism of Marine-Sourced Streptoglutarimide H against Lung Cancer Cells.

Hengju Ge1, Di Zhang1,2, Muran Shi3, Xiaoyuan Lian3, Zhizhen Zhang1.   

Abstract

In 2019, streptoglutarimide H (SGH) was characterized as a new glutarimide from the secondary metabolites produced by a marine-derived actinomycete Streptomyces sp. ZZ741 and shown to have in vitro antiglioma activity. However, the antiproliferative activity and potential mechanism of SGH against lung cancer cells have not yet been characterized. This study demonstrated that SGH significantly inhibited the proliferation of different lung cancer cells. In terms of mechanism of action, SGH downregulated cell cycle- and nucleotide synthesis-related proteins to block cell cycle at G0/G1 phase, reduced the expression levels of glycolytic metabolic enzymes to inhibit glycolysis, and downregulated the important cancer transcription factor c-Myc and the therapeutic target deubiquitinase USP28. Potent anticancer activity and multiple mechanisms indicated SGH to be a novel antitumor compound against lung cancer cells.

Entities:  

Keywords:  Streptoglutarimide H; USP28; antiproliferative activity; c-Myc; cell cycle block; glycolysis; lung cancer cells

Mesh:

Substances:

Year:  2021        PMID: 33572615      PMCID: PMC7911229          DOI: 10.3390/md19020079

Source DB:  PubMed          Journal:  Mar Drugs        ISSN: 1660-3397            Impact factor:   5.118


  37 in total

1.  CLINICAL EVALUATION OF STREPTOVITACIN A.

Authors:  J B FIELD
Journal:  Cancer Chemother Rep       Date:  1963-09

2.  USP28 and USP25 are downregulated by Vismodegib in vitro and in colorectal cancer cell lines.

Authors:  Hui Wang; Qian Meng; Yiluan Ding; Muya Xiong; Mengying Zhu; Yuanyuan Yang; Haixia Su; Lei Gu; Yechun Xu; Li Shi; Hu Zhou; Naixia Zhang
Journal:  FEBS J       Date:  2020-07-20       Impact factor: 5.542

Review 3.  Targeting cancer metabolism: a therapeutic window opens.

Authors:  Matthew G Vander Heiden
Journal:  Nat Rev Drug Discov       Date:  2011-08-31       Impact factor: 84.694

4.  Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells.

Authors:  Benjamin Kefas; Laurey Comeau; Nicholas Erdle; Emmitt Montgomery; Samson Amos; Benjamin Purow
Journal:  Neuro Oncol       Date:  2010-07-28       Impact factor: 12.300

5.  The ubiquitin-specific protease USP28 is required for MYC stability.

Authors:  Nikita Popov; Michael Wanzel; Mandy Madiredjo; Dong Zhang; Roderick Beijersbergen; Rene Bernards; Roland Moll; Stephen J Elledge; Martin Eilers
Journal:  Nat Cell Biol       Date:  2007-06-10       Impact factor: 28.824

Review 6.  MYC degradation.

Authors:  Amy S Farrell; Rosalie C Sears
Journal:  Cold Spring Harb Perspect Med       Date:  2014-03-01       Impact factor: 6.915

Review 7.  Ubiquitin ligases in oncogenic transformation and cancer therapy.

Authors:  Daniela Senft; Jianfei Qi; Ze'ev A Ronai
Journal:  Nat Rev Cancer       Date:  2017-12-15       Impact factor: 60.716

8.  Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme.

Authors:  Amparo Wolf; Sameer Agnihotri; Johann Micallef; Joydeep Mukherjee; Nesrin Sabha; Rob Cairns; Cynthia Hawkins; Abhijit Guha
Journal:  J Exp Med       Date:  2011-01-17       Impact factor: 14.307

Review 9.  Targeting oncogenic Myc as a strategy for cancer treatment.

Authors:  Hui Chen; Hudan Liu; Guoliang Qing
Journal:  Signal Transduct Target Ther       Date:  2018-02-23

10.  Quinoline 3-sulfonamides inhibit lactate dehydrogenase A and reverse aerobic glycolysis in cancer cells.

Authors:  Julia Billiard; Jennifer B Dennison; Jacques Briand; Roland S Annan; Deping Chai; Mariela Colón; Christopher S Dodson; Seth A Gilbert; Joel Greshock; Junping Jing; Hong Lu; Jeanelle E McSurdy-Freed; Lisa A Orband-Miller; Gordon B Mills; Chad J Quinn; Jessica L Schneck; Gilbert F Scott; Anthony N Shaw; Gregory M Waitt; Richard F Wooster; Kevin J Duffy
Journal:  Cancer Metab       Date:  2013-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.